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OBJECTIVE — Adipocyte fatty acid–binding protein (A-FABP) is a major cytoplasmic pro-
tein in adipocytes and macrophages and is closely associated with metabolic syndrome, type 2
diabetes, and atherosclerosis. Here, we investigated whether A-FABP was associated with
nonalcoholic fatty liver disease (NAFLD) in type 2 diabetes.
RESEARCH DESIGN AND METHODS — We enrolled 181 type 2 diabetic patients.
Clinical and biochemical metabolic parameters were measured. The severity of NAFLD was
measured by ultrasound. A-FABP, adiponectin, and retinol-binding protein-4 (RBP-4) were
determined by enzyme-linked immunosorbent assay.
RESULTS — A-FABP levels, deﬁned as more than a moderate degree of fatty liver compared
with men, those without metabolic syndrome, and those without NAFLD, were higher in
women, patients with metabolic syndrome, and patients with overt NAFLD, respectively. Adi-
ponectin was decreased according to the severity of NAFLD, but RBP-4 showed no difference.
Age- and sex-adjusted A-FABP showed positive correlations with BMI, waist-to-hip ratio, waist
circumference, triglycerides, -glutamyltransferase, fasting insulin, homeostasis model assess-
ment of insulin resistance (HOMA-IR), A1C, and C-reactive protein (CRP) but showed negative
correlation with HDL cholesterol. The odds ratio (OR) for the risk of overt NAFLD with increas-
ing levels of sex-speciﬁc A-FABP was signiﬁcantly increased (OR 2.90 [95% CI 1.15–7.29] vs.
7.87 [3.20–19.38]). The OR in the highest tertile of A-FABP remained signiﬁcant after adjust-
ments for BMI, waist circumference, A1C, HDL cholesterol, triglycerides, HOMA-IR, CRP, and
hepatic enzymes.
CONCLUSIONS — Our study demonstrates that serum A-FABP is signiﬁcantly associated
with NAFLD in type 2 diabetes, independent of BMI, waist circumference, HOMA-IR, A1C,
triglycerides, HDL cholesterol, and CRP.
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N
onalcoholic fatty liver disease
(NAFLD) is one of the most com-
mon causes of chronic elevation of
hepatic enzymes in the general popula-
tionwithoutknownliverdisease.NAFLD
is observed in 20–30% of the total popu-
lation (1) and in 75% of type 2 diabetic
patients (2,3) in developed countries.
NAFLD is characterized by hepatic insu-
lin resistance. In epidemiologic studies,
NAFLD has been reported to be closely
associated with obesity, dyslipidemia,
and diabetes (4–6). In prospective stud-
ies, NAFLD was a risk factor for type 2
diabetes and cardiovascular disease inde-
pendent of the classic risk factors (7,8).
Hence, NAFLD is considered a hepatic
manifestation of metabolic syndrome.
Adipocyte fatty acid–binding protein
(A-FABP; also known as FABP-4 or aP2)
is a major cytoplasmic protein and is in-
volved in the regulation of lipid metabo-
lism. A-FABP is expressed abundantly in
mature adipocytes and activated macro-
phages. A-FABP binds fatty acid ligands
with high afﬁnity and functions in intra-
cellularfattyacidtrafﬁcking,regulationof
lipidmetabolism,andmodulationofgene
expression (9,10). In obese mice lacking
A-FABP, dyslipidemia and peripheral in-
sulin resistance are improved and -cell
function is preserved (11). Boord et al.
(12) reported that combined adipocyte-
macrophage fatty acid–binding protein
deﬁciency improves glucose and lipid
metabolism, reduces atherosclerosis, and
improves survival in apoE
-/- mice. In
cross-sectional studies, A-FABP was
closely associated with obesity and meta-
bolic syndrome (13,14). In prospective
studies, A-FABP levels predicted the de-
velopment of metabolic syndrome and
type 2 diabetes (15,16). Furthermore,
Yeung et al. (17) reported that A-FABP
levelswereindependentlyassociatedwith
carotid atherosclerosis. Tuncman et al.
(18) reported that individuals with an
aP2 variant had lower triglycerides and
a reduced risk of coronary heart disease
and obesity-induced type 2 diabetes.
TheseﬁndingssuggestedthatA-FABPis
closely associated with insulin resis-
tance and plays a central role in the de-
velopment of metabolic syndrome, type
2 diabetes, and atherosclerosis. Maeda
et al. (19) demonstrated protection
against fatty liver disease in mice lack-
ingaP2andmal1onhigh-fatdiet.How-
ever, a relationship between A-FABP
and NAFLD, a hepatic manifestation of
metabolic syndrome, has not yet been
established in a human study.
We hypothesized that patients with
NAFLD might have higher A-FABP levels
and that A-FABP might show a positive
correlationwiththeseverityofNAFLDon
ultrasound.Totestthishypothesis,wein-
vestigated the relationship between se-
rum A-FABP levels and NAFLD in type 2
diabetic patients.
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METHODS— Weenrolled181type2
diabetic subjects using the following in-
clusion criteria: 1) ages 35 and 75
years, 2) serum creatinine levels less than
1.4 mg/dl and albumin excretion rate less
than300mg/day,3)hepaticenzymeslev-
els less than three times upper normal,
and 4) alcohol consumption less than 20
g/day. Patients with known hepatic dis-
ease, cardiovascular disease, acute or
chronic inﬂammation, and malignancy
were excluded. The mean age of the sub-
jectswas54.310.4years,and55.2%of
thetotalsubjectsweremale.Theprotocol
was approved by the ethics committee of
Yonsei University Wonju College of Med-
icine. All of the subjects gave written in-
formed consent, and all of the reported
investigations were carried out according
to the principles of the Declaration of
Helsinki (the year 2000 revision).
Alcoholintake,smokinghabits,med-
ication history, and medical history were
assessed using a standardized question-
naire. Anthropometric data including
weight, height, waist and hip circumfer-
ence, and blood pressure were assessed.
BMIwascalculatedasweightinkilograms
divided by the square of height in meters
(kg/m
2).Allbloodsampleswereobtained
after overnight fasting. Fasting plasma
glucose, insulin, A1C, urine albumin ex-
cretion rate, hepatic enzyme levels, high-
sensitivity C-reactive protein (CRP), and
lipid proﬁles were measured.
All of the abdominal ultrasounds
were performed by the same specialist.
TheseverityofNAFLDonultrasoundwas
graded as follows: mild (grade 1), deﬁned
as a slight diffuse increase in liver echoge-
nicity in the hepatic parenchyma with
normal visualization of the diaphragm
and the portal veins; moderate (grade 2),
deﬁnedasamoderatelydiffuseincreasein
liverechogenicitywithaslightlyimpaired
visualization of the diaphragm and the
portalveins;andsevere(grade3),deﬁned
as a marked increase in liver echogenicity
with poor or no visualization of the dia-
phragm and the portal veins. We deﬁned
overt NAFLD in this study as more than a
moderate degree of fatty liver.
Adiponectinandretinol-bindingpro-
tein-4 (RBP-4) levels were determined by
ELISA (Adipogen, Seoul, Korea). A-FABP
levels were also assessed by ELISA (Bio
vendor Laboratory Medicine, Modrice,
Czech Republic). Insulin resistance was
measured by the homeostasis model of
assessmentforinsulinresistance(HOMA-
IR). The HOMA-IR index was calculated
using the following formula: fasting
plasma glucose (mg/dl)  fasting insulin
/405 (U/ml).
Statistical analyses
Statistical analysis was performed using
SPSS (version 13.0; SPSS, Chicago, IL).
Data are presented as means  SD and as
a number (in percentages) for categorical
measures. Data that were not normally
distributed were logarithmically trans-
formed before analysis. For continuous
variables, the differences between groups
were compared using either an unpaired
Student’s t test or one-way ANOVA. The

2 test was used to compare categorical
variables between groups. Correlations of
A-FABP with various metabolic parame-
Table 1—Characteristics of the subjects according to the severity of fatty liver
Normal Mild Moderate P
n 42 78 61
Age (years) 53.4  10.5 54.0  9.3 55.2  11.8 0.7
Sex (male %) 64.3 57.7 45.9 0.2
Hypertension (%) 52.4 34.6 44.1 0.2
Current smoker (%) 26.2 23.1 11.5 0.1
PPAR agonists use (%) 9.5 5.1 8.2 0.6
Insulin use (%) 7.1 5.1 1.6 0.4
ARB and ACEi use (%) 40.5 21.8 23.0 0.06
Statins use (%) 21.4 12.8 19.7 0.4
Diabetes duration (years) 6.7  6.0 4.6  4.7 4.6  6.3 0.1
Systolic BP (mmHg) 129.6  21.1 131.5  13.7 134.8  17.2 0.3
Diastolic BP (mmHg) 75.4  15.0 77.1  8.2 78.7  11.6 0.4
BMI (kg/m
2) 24.0  2.3 25.3  3.3* 27.1  3.4‡ 0.001
Waist circumference (cm) 84.8  8.0 88.1  7.5* 91.2  8.7‡ 0.001
Male 85.8  7.1 88.6  6.7 92.7  6.7† 0.001
Female 83.1  9.4 87.4  8.5 91.8  10.1† 0.01
WHR 0.91  0.06 0.93  0.05* 0.94  0.05† 0.003
Total cholesterol (mg/dl) 180.3  34.4 193.4  39.5 190.3  39.1 0.2
Triglycerides (mg/dl) 149.4  101.8 182.0  115.1 186.7  83.4 0.2
HDL cholesterol (mg/dl) 50.0  13.1 48.0  12.1 47.8  8.8 0.6
Male 48.8  9.4 46.6  10.2 48.1  8.7 0.6
Female 52.1  18.3 49.4  14.4 47.5  8.9 0.5
LDL cholesterol (mg/dl) 104.9  30.8 112.4  36.6 111.5  33.7 0.5
AST (units/l) 20.5  6.5 24.9  10.2 33.8  19.2‡ 0.001
ALT (units/l) 23.5  10.2 32.6  22.6* 42.6  24.7‡ 0.001
GGT (units/l) 27.8  18.5 42.0  35.9* 52.1  41.9† 0.003
A-FABP total (g/l) 13.9  10.1 15.9  10.1 24.7  17.9‡ 0.001
Male 12.3  9.0 13.6  10.2 15.9  6.6 0.3
Female 16.7  11.6 19.1  9.3 32.2  20.9† 0.001
RBP-4 total (g/ml) 72.7  28.7 74.1  32.6 72.1  26.1 0.9
Male 76.2  23.3 83.3  38.1 77.8  23.6 0.6
Female 66.3  36.5 61.6  17.0 67.3  27.5 0.7
Adiponectin total (g/ml) 5.0  2.2 4.1  2.6* 3.8  2.3† 0.03
Male 5.1  2.2 3.5  2.0† 2.7  1.2‡ 0.001
Female 5.0  2.3 4.9  3.2 4.7  2.5 0.9
CRP (mg/l) 1.50  2.50 2.39  4.46 3.60  4.66* 0.04
FPG (mg/dl) 207.9  142.5 180.0  68.8 174.5  58.5 0.2
Fasting insulin (U/ml) 6.4  6.7 7.5  6.1 11.1  8.2† 0.001
HOMA-IR 3.1  3.5 3.1  2.3 4.6  3.6* 0.01
A1C (%) 8.9  2.7 8.2  2.2 8.8  2.0 0.2
24-h albumin (mg/day) 40.3  45.1 31.4  38.6 30.3  40.6 0.5
Serum creatinine (mg/dl) 0.87  0.28 0.78  0.17* 0.80  0.18 0.07
Metabolic syndrome (n 	%
) 17 (41.5) 55 (71.4) 47 (77.0) 0.001
Data are means  SD, unless indicated otherwise. P value: the difference among three groups using ANOVA
test. *P  0.05 compared with normal. †P  0.01 compared with normal. ‡P  0.001 compared with
normal.ACEi,angiotensinconvertingenzymeinhibitors;ARB,angiotensinIIreceptorblockers;ALT,alanine
aminotransferase; AST, aspartate aminotransferase; BP, blood pressure; FPG, fasting plasma glucose; GGT,
-glutamyltransferase.
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tion and multiple regression analysis after
adjustments for age and sex. Logistic re-
gression analysis was performed to assess
the odds ratio (OR) of the metabolic pa-
rametersforthepresenceofovertNAFLD
afteradjustmentsforageandsex.A-FABP
levels were grouped into tertiles in a sex-
speciﬁc manner. Multiple logistic regres-
sionanalysiswasusedtoassesstheORfor
the presence of overt NAFLD in subjects
withthehigherA-FABPtertilescompared
with those with the lowest tertile. Two-
sided values of P  0.05 were considered
signiﬁcant.
RESULTS
Baseline characteristics of the
subjects
DurationofdiabetesandmeanA1Clevels
for all of the subjects were 5.1 years and
8.6%, respectively. Of the 181 type 2 di-
abetic patients, the users of peroxisome
proliferator–activated receptor-
(PPAR-) agonists, insulin, statins, and
angiotensin-converting enzyme inhibi-
tors and/or angiotensin II receptor block-
ers were 7.2, 4.4, 17.1, and 26.5%,
respectively. The percentage of patients
with metabolic syndrome and NAFLD
were 66.5 and 76.8%, respectively. As
shown in Table 1, all subjects were di-
vided into three subgroups according to
the severity of their fatty liver disease:
normal, mild degree, and more-than-
moderatedegree.Theproportionsofeach
group were 23.2, 43.1, and 33.7%, re-
spectively. Patients with overt NAFLD
had higher BMI, waist circumference,
waist-to-hip ratio (WHR), hepatic en-
zymes, CRP, A-FABP, and HOMA-IR
(P  0.05) and had lower adiponectin
levels (P  0.05) compared with those
withoutNAFLD.Also,patientswithovert
NAFLD were more likely to have meta-
bolic syndrome than those without. Se-
rum A-FABP levels were signiﬁcantly
higher in women than men (24.0  16.7
vs. 13.9  9.0 g/l; P  0.001). Also,
A-FABP levels in patients with overt
NAFLD and metabolic syndrome were
signiﬁcantly higher than in those without
NAFLD (24.7  17.9 vs. 15.3  10.2
g/l; P  0.001) and those without met-
abolic syndrome (20.6  14.4 vs. 14.2 
12.2 g/l; P  0.004). A-FABP levels in
users of PPAR- agonists were slightly
higher compared with nonusers, but this
difference was not signiﬁcant.
Correlations between serum A-FABP
levels and various metabolic
parameters
As shown in Table 2, age- and sex-
adjusted A-FABP showed signiﬁcant pos-
itive correlations with BMI, WHR, waist
circumference, triglycerides, -glutamyl-
transferase, fasting insulin, HOMA-IR,
A1C, and CRP. However, A-FABP was
negatively correlated with HDL choles-
terol (P  0.05). However, there were no
signiﬁcant correlations between age- and
sex-adjusted A-FABP and adiponectin,
RBP-4, and the use of PPAR- agonists,
statins, or antihypertensive drugs (data
not shown).
OR of the metabolic parameters for
the presence of overt NAFLD
In multivariate linear regression analysis
after adjustment for age and sex, A-FABP
was signiﬁcantly associated with overt
NAFLD independent of BMI, waist cir-
cumference, HOMA-IR, and A1C (P 
0.01) (data not shown). In multiple logis-
ticregressionanalysisafteradjustmentfor
age and sex, high A-FABP was associated
with overt NAFLD (OR 2.87 [95% CI
1.47–5.61]; P  0.002). Also, waist cir-
cumference,BMI,WHR,HOMA-IR,CRP,
triglycerides, aspartate aminotransferase,
alanine aminotransferase, and -gluta-
myltransferase were signiﬁcantly associ-
Table 2—Correlation between A-FABP levels and various metabolic parameters
A-FABP*
Model 1 Model 2
rP  P
Male sex 0.43 0.001 — —
PPAR agonists use 0.09 0.2 — —
ACEi or ARB use 0.05 0.3 — —
BMI 0.22 0.003 0.22 0.004
WHR 0.33 0.001 0.35 0.001
Waist circumference 0.28 0.001 0.32 0.001
Current smoking 0.22 0.003 0.03 0.7
Triglycerides* 0.15 0.03 0.20 0.003
HDL cholesterol 0.18 0.01 0.17 0.03
GGT* 0.12 0.06 0.22 0.001
Fasting insulin 0.18 0.01 0.17 0.03
HOMA-IR* 0.22 0.003 0.22 0.004
A1C 0.19 0.008 0.23 0.003
Metabolic syndrome 0.31 0.001 0.25 0.001
CRP* 0.32 0.001 0.30 0.001
Adiponectin* 0.09 0.1 — —
Model 1: Pearson correlation coefﬁcient. Model 2: Regression coefﬁcient adjusted for age and sex. *Log
transformed data before analysis. ACEi, angiotensin converting enzyme inhibitors; ARB, angiotensin II
receptor blockers; GGT, -glutamyltransferase.
Table3—ORofmetabolicparametersforthepresenceofovertfattyliverafteradjustmentfor
age and sex
OR 95% CI P
BMI 1.24 1.11–1.38 0.001
Waist circumference 1.07 1.02–1.13 0.003
WHR 2.20 1.18–4.11 0.01
HOMA-IR* 1.46 1.07–1.98 0.02
A-FABP* 2.87 1.47–5.61 0.002
CRP* 2.40 1.36–4.23 0.002
Triglycerides* 1.99 1.07–3.68 0.03
ALT* 3.97 2.10–7.49 0.001
AST* 7.16 2.93–17.45 0.001
GGT* 2.55 1.53–4.23 0.001
Data are OR (95% CI) unless otherwise indicated. *Log transformed data before analysis. ALT, alanine
aminotransferase; AST, aspartate aminotransferase; GGT, -glutamyltransferase.
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(Table 3). As shown in Table 4, the pa-
tients in the highest tertile of sex-speciﬁc
A-FABP had signiﬁcantly higher BMI,
waist circumference, WHR, triglycerides,
A1C, and serum creatinine but had lower
HDL cholesterol and estimated glomeru-
lar ﬁltration rate (GFR) compared with
those in the lowest tertile (P  0.05). Pa-
tients in the higher tertiles of sex-speciﬁc
A-FABPhadhigherORforthepresenceof
overt NAFLD compared with those in the
lowest tertile (2.90 [1.15–7.29] vs. 7.87
[3.20–19.38]). The OR in the highest
tertile of sex-speciﬁc A-FABP remained
signiﬁcant after adjustment for BMI,
waist circumference, A1C, HDL choles-
terol, HOMA-IR, CRP, triglycerides,
and hepatic enzymes (8.53 [2.63–
27.65]) (Table 5).
CONCLUSIONS — In the present
study, we demonstrate that serum A-
FABP levels in type 2 diabetic patients are
closely associated with NAFLD indepen-
dent of BMI, waist circumference,
HOMA-IR, A1C, triglycerides, HDL cho-
lesterol, and CRP levels. Patients in the
highest tertile of A-FABP were eight times
more likely to have overt NAFLD com-
pared with those in the lowest tertile. In
animal studies, there was no protection
against fatty liver disease in aP2-deﬁcient
mice because of compensation through
increased expression of mal1 (20). How-
ever, a profound protection against fatty
liverdiseasewasshowninaP2-mal1com-
bined–deﬁcient mice on high-fat diet
(19). Also, Cao et al. (21) demonstrated
that there was striking protection from
liver fatty inﬁltration in ob/ob-aP2-mal1–
deﬁcient mice with strong suppression of
liver stearoyl-CoA desaturase-1. Further-
more, Furuhashi et al. (22) reported that
fatty inﬁltration of the liver was attenu-
ated and total liver triglyceride content
was reduced in aP2-inhibitor–treated
ob/ob mice. However, the relationship be-
tween A-FABP and fatty liver disease has
not yet been established in a human
study. This study is the ﬁrst to demon-
strateanassociationbetweenA-FABPand
NAFLD in type 2 diabetic patients. Taken
together, these ﬁndings suggest that
chemical inhibition of A-FABP might
show beneﬁcial effects against fatty liver
disease.
Like previous studies, serum A-FABP
levels in our type 2 diabetic patients were
associated with markers of obesity, dys-
lipidemia, hyperglycemia, insulin resis-
tance, and inﬂammation. However, there
are discrepancies in the correlation be-
tween A-FABP and adiponectin. Xu et al.
(13) reported that A-FABP in nondiabetic
subjects was positively correlated with
HOMA-IR but was negatively correlated
with adiponectin. On the contrary, Cabre
et al. (23) reported that A-FABP in type 2
diabetes was positively correlated with
adiponectin but was not correlated with
HOMA-IR.Inourtype2diabeticpatients,
A-FABP was not correlated with adi-
ponectin but was positively correlated
with HOMA-IR. Differences in the adi-
posity of the populations and sex differ-
ence of A-FABP and adiponectin levels
mightpartlyexplainthisdiscrepancy.Re-
cently,Cabreetal.(24)reportedthathigh
A-FABP plasma concentrations were as-
Table 4—Characteristics according to A-FABP tertile levels
A-FABP tertile
P
1( 8.6 g/l [men],
150 g/l [women])
2 (8.6–14.3 g/l [men],
15.0–24.1 g/l [women])
3( 14.3 g/l [men],
24.1 g/l [women])
Age (years) 53.1  8.1 55.3  11.4 54.4  11.4 0.5
BMI (kg/m
2) 24.6  3.2 25.8  3.1 26.3  3.5† 0.02
Waist circumference (cm) 85.0  7.0 89.3  7.7† 91.6  9.2‡ 0.001
WHR 0.91  0.05 0.93  0.05* 0.95  0.06‡ 0.001
Triglycerides (mg/dl) 148.9  94.1 190.1  124.3* 187.3  82.1* 0.05
HDL cholesterol (mg/dl) 52.6  11.6 45.7  9.3† 46.7  11.9† 0.001
A-FABP (g/l) 9.0  2.9 14.6  4.2† 31.1  16.9‡ 0.001
RBP-4 (g/ml) 67.1  19.6 78.6  34.4 73.4  31.5 0.1
Adiponectin (g/ml) 4.3  2.0 3.9  2.2 4.4  3.0 0.5
CRP (mg/l) 1.70  3.55 2.57  4.14 3.39  4.69* 0.1
FPG (mg/dl) 172.5  69.2 188.2  119.3 192.5  70.4 0.4
Fasting insulin (U/ml) 7.7  7.6 7.3  6.2 10.1  7.5 0.07
HOMA-IR 3.2  3.3 3.3  3.2 4.3  2.8 0.08
A1C (%) 8.1  2.0 8.6  2.3 9.1  2.4* 0.04
24-h albumin (mg/day) 29.3  38.2 29.0  26.3 40.4  52.6 0.2
Serum creatinine (mg/dl) 0.76  0.16 0.82  0.24 0.84  0.21* 0.1
Estimated GFR (ml/min/1.73 m
2) 103.8  19.6 96.5  26.7 94.5  23.4* 0.08
Metabolic syndrome (n 	%
) 25 (43.1) 46 (76.7)‡ 48 (78.7)‡ 0.001
DataaremeansSDunlessindicatedotherwise.PthedifferenceamongthreegroupsusingANOVAtest.*P0.05comparedwithtertile1.†P0.01compared
with tertile 1. ‡P  0.001 compared with tertile 1. FPG, fasting plasma glucose.
Table5—ORforthepresenceofovertfattyliveraccordingtothetertileofsex-speciﬁcA-FABP
levels
OR (95% CI)
Tertile 1 Tertile 2 Tertile 3
Model 1 1 2.90 (1.15–7.29) 7.87 (3.20–19.38)
Model 2 1 3.14 (0.99–9.99) 8.53 (2.63–27.65)
DataareOR(95%CI).Model1:unadjusted.Model2:model1
adjustmentsforBMI,waistcircumference,
triglycerides, HDL cholesterol, A1C, HOMA-IR, CRP, alanine aminotransferase, aspartate aminotransferase,
and -glutamyltransferase.
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lowGFRintype2diabeticpatients.Inour
study, patients with estimated GFR 60
ml/minper1.73m
2wereonly2.8%ofthe
totalsubjects.Inmultipleregressionanal-
ysis, A-FABP was associated with serum
creatinine after adjustments for age, sex,
and BMI but was not associated with es-
timated GFR (data not shown).
Similar to previous studies (15,23),
sex difference in A-FABP was observed in
our study. A-FABP was signiﬁcantly
higher in women than in men. The sex
difference is explained partly by the
higher fat and subcutaneous fat percent-
ages in women compared with men be-
cause adipose tissue is a major source of
circulating A-FABP and A-FABP expres-
sion is higher in subcutaneous fat than in
visceral fat. In our data, patients with
NAFLD had higher A-FABP levels than
those without NAFLD. In women, A-
FABPlevelsinpatientswithovertNAFLD
were signiﬁcantly higher than in those
without overt NAFLD. However, it was
not signiﬁcant in men. These ﬁndings
suggest that A-FABP is a more speciﬁc
markerofNAFLDinwomenthaninmen.
This study has several limitations.
One limitation of the present study is that
it is cross-sectional. We could not prove a
causal link between serum A-FABP levels
and the development of NAFLD. Second,
wecouldnotanalyzeourdatastratiﬁedby
sexbecauseofthesmallsamplesize.Nev-
ertheless,weassessedtheORforthepres-
ence of NAFLD according to the sex-
speciﬁc tertiles of A-FABP. Third, the
severity of NAFLD was assessed by ultra-
soundinthisstudybutwasnotconﬁrmed
pathologically. Although liver biopsy is
the gold standard to assess pathologic
grading of NAFLD, it is difﬁcult to per-
form liver biopsies for the assessment of
NAFLD in clinical practice. It has been
reported that the sensitivity and speciﬁc-
ity of ultrasound in the diagnosis of fatty
liver, as assessed on liver biopsy, were
60–94 and 84–95%, respectively (25).
In conclusion, we demonstrated that
serum A-FABP was closely associated
with NAFLD in type 2 diabetic patients.
Our data suggest that A-FABP may be an
independent marker of NAFLD in type 2
diabetes, independent of BMI, waist cir-
cumference, HOMA-IR, A1C, triglycer-
ides, HDL cholesterol, and CRP levels.
Largepopulation-basedprospectivestud-
ies are warranted to conﬁrm whether A-
FABP is an independent predictor of
NAFLD and whether it plays a causative
role in the pathogenesis of NAFLD.
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